Arcus Presents New Data from ARC-20 that Demonstrate the Opportunity for Casdatifan to Become a Foundational Treatment Across All Lines of Therapy in Kidney Cancer
Arcus Biosciences presented new ARC-20 data showing casdatifan, its next-generation HIF-2α inhibitor, outperforming third-party benchmarks across first-, second- and late-line clear cell renal cell carcinoma. In the first line, casdatifan plus zimberelimab delivered 86% and 69% landmark PFS at 6 and 12 months versus 65% and 50% for the ipilimumab/nivolumab standard of care. In the second line, casdatifan plus cabozantinib achieved a 14.5-month median PFS versus ~10 months for cabozantinib alone, and late-line monotherapy produced a 35-month median OS — more than a year beyond the only approved HIF-2α inhibitor.
Key figures
- Drug Name
- casdatifan (AB521)
- Phase Of Trial
- Phase 3 (PEAK-1 ongoing; PEAK-20 planned)
- Data cut off
- Sept. 4, 2026
- Late line cor
- 36%
- First line cor
- 50%
- Second line cor
- 44%
- Monotherapy cohort n
- 121
- Late line median os months
- 35
- First line 6mo landmark pfs
- 86%
- Late line median pfs months
- 13
- First line 12mo landmark pfs
- 69%
- Second line 18mo landmark os
- 77%
- Second line median pfs months
- 14.5
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.